Roger J. Bedimo
Experienced in Shingles

Dr. Roger J. Bedimo

Infectious Disease
4500 S Lancaster Rd, Suite 111-d, 
Dallas, TX 
30 Years of Experience
Experienced in Shingles
4500 S Lancaster Rd, Suite 111-d, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roger Bedimo is an Infectious Disease provider in Dallas, Texas. Dr. Bedimo has been practicing medicine for over 30 years and is rated as an Experienced provider by MediFind in the treatment of Shingles. His top areas of expertise are HIV/AIDS, Hepatitis C, Sepsis, and Hepatitis.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Shingles.

Specialties
Infectious Disease
Licenses
Internal Medicine in AL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

4500 S Lancaster Rd, Suite 111-d, Dallas, TX 75216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model
Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model
Enrollment Status: Terminated
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Other
Study Phase: Not Applicable
Impact of HCV Therapy on Cardiovascular Risk and Bone Health
Impact of HCV Therapy on Cardiovascular Risk and Bone Health
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

116 Total Publications

Underestimation of body mass index and weight misperception are common in people with HIV.
Underestimation of body mass index and weight misperception are common in people with HIV.
Journal: AIDS care
Published: October 01, 2025
Similar Doctors
Experienced in Shingles
Dr. Cedric W. Spak
Infectious Disease | Internal Medicine
Experienced in Shingles
Dr. Cedric W. Spak
Infectious Disease | Internal Medicine

Texas Centers For Infectious Disease Associates

3410 Worth St, Ste 780, 
Dallas, TX 
 (6.6 miles away)
972-449-0540
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cedric Spak is an Infectious Disease specialist and an Internal Medicine provider in Dallas, Texas. Dr. Spak has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Shingles. His top areas of expertise are Actinomycosis, Cytomegalic Inclusion Disease, Cytomegalovirus Infection, and Osteomyelitis.

Experienced in Shingles
Dr. Ricardo M. La Hoz
Infectious Disease
Experienced in Shingles
Dr. Ricardo M. La Hoz
Infectious Disease

University Of Texas Southwestern Medical Center At Dallas

6202 Harry Hines Blvd, 
Dallas, TX 
 (9.3 miles away)
469-488-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ricardo La Hoz is an Infectious Disease provider in Dallas, Texas. Dr. La Hoz is rated as a Distinguished provider by MediFind in the treatment of Shingles. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Nocardiosis, and Cryptococcosis.

Experienced in Shingles
Dr. Shantala R. Samart
Infectious Disease | Internal Medicine
Experienced in Shingles
Dr. Shantala R. Samart
Infectious Disease | Internal Medicine

ID Partners PA

350 Matlock Rd, Ste, Suite 201, 
Mansfield, TX 
 (22.2 miles away)
682-205-3501
Experience:
21+ years
Languages Spoken:
English
See accepted insurances

Shantala Samart is an Infectious Disease specialist and an Internal Medicine provider in Mansfield, Texas. Dr. Samart has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Shingles. Her top areas of expertise are Sepsis, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), and Lymphangitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bedimo's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile